MENTOR, Ohio, Jan. 6 /PRNewswire-FirstCall/ -- STERIS Corporation today announced that Timothy L. Chapman has joined the Company as senior vice president, Business Strategy, filling a newly created position.
Chapman, age 43, will become a member of STERIS Corporation’s senior management team, reporting to Les C. Vinney, president and chief executive officer. He has responsibility for leading STERIS’s strategic planning, business development and supply chain management activities. Mr. Chapman will also have responsibility for leading the Company’s multi-year Performance Transformation program designed to improve business and management processes and establish a common culture at STERIS.
“Having served STERIS in a consulting role for several years, Tim joins us with a deep understanding of our operations,” said Vinney. “In addition, his wealth of operational and healthcare industry experience, managing issues for an array of institutions such as hospital, medical supply and insurance clients, makes him a valued addition as he brings a unique perspective to our organization.”
Mr. Chapman joins STERIS Corporation from McKinsey & Company’s Cleveland office, where he was most recently a director responsible for managing a number of client service efforts. During his more than 20 years with McKinsey, he founded and led the Purchasing and Supply Management practice, and went on to lead the Operations Practice, which encompasses manufacturing, product development, supply chain, service operations and purchasing. For 15 years, Mr. Chapman has served as a leader in McKinsey’s Healthcare Practice, working closely with numerous healthcare institutions on a broad range of organizational, strategic and operational issues.
Mr. Chapman earned a bachelor’s degree in Economics from Dartmouth College and a master’s degree in Business Administration with distinction from the Amos Tuck School at Dartmouth. He is a board member of the Make-A-Wish Foundation of Greater Ohio and Kentucky, and previously served that organization as a national board member.
About STERIS
The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company’s more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.
This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company’s Form 10-K and other securities filings. Many of these important factors are outside STERIS’s control. No assurances can be provided as to any future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company’s business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in foreign currencies of countries where the Company does a sizeable amount of business, and (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company’s products and services.
STERIS Corporation
CONTACT: Aidan Gormley, Senior Director, Corporate Communications andInvestor Relations of STERIS Corporation, +1-440-392-7607
Web site: http://www.steris.com//
